Ignite Creation Date:
2025-12-25 @ 4:34 AM
Ignite Modification Date:
2026-03-30 @ 5:25 AM
Study NCT ID:
NCT05429918
Status:
UNKNOWN
Last Update Posted:
2022-06-23
First Post:
2021-07-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Ibrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged ≤65 Years
Sponsor:
Peking University Third Hospital
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
M2021028
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | OTHER | View |
| None | OTHER | View |
| None | OTHER_GOV | View |
| None | OTHER | View |
| None | OTHER | View |
| None | OTHER | View |
| None | OTHER | View |
| None | OTHER | View |
| None | OTHER | View |
| None | OTHER | View |
| None | OTHER | View |
| None | OTHER | View |
| None | OTHER | View |
| None | OTHER | View |
| None | OTHER | View |
| None | OTHER | View |
| None | OTHER | View |
| None | OTHER | View |